Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An expanded access programme to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 ("COVID-19") induced Acute Respiratory Distress Syndrome ("ARDS"), an immediately life-threatening condition

Next Previous
Trial Profile

An expanded access programme to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 ("COVID-19") induced Acute Respiratory Distress Syndrome ("ARDS"), an immediately life-threatening condition

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DMI 9523 (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 02 Apr 2020 According to an Ampio Pharmaceuticals media release, additional information about the potential suitability of the anti-inflammatory properties of Ampion being used for this clinical indication (ARDS) is included in a companion white paper summary titled, "Rationale and scientific evidence for the use of Ampion in the treatment of Acute Respiratory Distress Syndrome secondary to SARS-COV-2".
  • 02 Apr 2020 According to an Ampio Pharmaceuticals media release, the company's application to the FDA for a clinical study of Ampion to treat COVID-19 induced ARDS was featured on a FOX NEWS segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug", reported by an affiliated television station in Denver, Colorado.
  • 30 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top